Volume 20, Number 6—June 2014
Dispatch
Timeliness of Yellow Fever Surveillance, Central African Republic
Table 2
Factor | Mean timeliness, d | Adjusted time ratio (95% CI) | p value† |
---|---|---|---|
Age, y | |||
<14 | 15.3 | 1.00 | NA |
15–24 | 16.5 | 1.13 (1.08–1.18) | NA |
25–34 | 16.8 | 1.15 (1.09–1.21) | NA |
≥35 |
18.6 |
1.21 (1.15–1.27) |
<0.001 |
Sex | |||
M | 16.6 | 1.00 | NA |
F |
16.5 |
1.01 (0.98–1.05) |
0.43 |
Onset during rainy season | |||
No | 16.7 | 1.00 | NA |
Yes |
16.5 |
1.01 (0.97–1.04) |
NA |
Province of residence | |||
Bangui | 14.8 | 1.00 | NA |
Ombella M’Poko | 15.7 | 1.07 (1.02–1.12) | NA |
Lobaye | 16.8 | 1.18 (1.09–1.28) | NA |
Sangha Mbaéré | 17.6 | 1.17 (0.93–1.46) | NA |
Mambéré Kadéi | 18.0 | 1.21 (1.03–1.41) | NA |
Nana Mambéré | 20.7 | 1.43 (1.22–1.67) | NA |
Ouham Péndé | 15.5 | 1.10 (1.01–1.19) | NA |
Ouham | 17.0 | 1.19 (1.08–1.32) | NA |
Nana Grigbizi | 22.9 | 1.56 (1.39–1.77) | NA |
Kemo | 19.4 | 1.35 (1.21–1.51) | NA |
Bamingui Bangoran | 17.5 | 1.24 (1.01–1.53) | NA |
Ouaka | 19.2 | 1.34 (1.24–1.46) | NA |
Basse Kotto | 16.5 | 1.19 (1.10–1.29) | NA |
Vakaga | 20.1 | 1.38 (1.16–1.65) | NA |
Haute Kotto | 17.4 | 1.25 (1.13–1.39) | NA |
Mbomou | 26.2 | 1.86 (1.66–2.09) | NA |
Haut Mbomou |
23.9 |
1.72 (1.37–2.15) |
<0.001 |
Vaccination against yellow fever | |||
Never | 16.6 | 1.00 | NA |
>10 y ago | 16.9 | 1.01 (0.93–1.09) | NA |
≤10 y ago | 16.3 | 1.01 (0.96–1.05) | NA |
Unknown date |
16.1 |
1.06 (0.92–1.23) |
0.85 |
Year of onset | |||
2007 | 17.8 | 1.00 | NA |
2008 | 17.3 | 1.02 (0.95–1.09) | NA |
2009 | 14.7 | 0.91 (0.85–0.98) | NA |
2010 | 16.8 | 1.04 (0.97–1.12) | NA |
2011 | 17.8 | 1.10 (1.02–1.18) | NA |
2012 | 16.6 | 1.05 (0.96–1.15) | <0.001 |
*Adjusted time ratios are from a parametric survival model assuming log-normal distribution of the event times. A time ratio represents a relative increase in time between 2 groups. Timeliness was defined as the delay between the date of onset of jaundice (reported by the patient) and the date of ELISA result. NA, not applicable.
†By global Wald test.
1Current affiliation: European Hospital Georges Pompidou and Descartes University, Paris, France.
Page created: May 16, 2014
Page updated: May 16, 2014
Page reviewed: May 16, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.